Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MARIA BOTTAZZI and PETER HOTEZ.
MARIA BOTTAZZI
Connection Strength
25.573
PETER HOTEZ
  1. Human Schistosomiasis Vaccines as Next Generation Control Tools. Trop Med Infect Dis. 2023 Mar 14; 8(3).
    View in: PubMed
    Score: 0.835
  2. From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):495-500.
    View in: PubMed
    Score: 0.823
  3. A COVID Vaccine for All: This patent-free technology could finally inoculate the world. Sci Am. 2022 03 01; 326(3):10.
    View in: PubMed
    Score: 0.777
  4. Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. Annu Rev Med. 2022 01 27; 73:55-64.
    View in: PubMed
    Score: 0.756
  5. COVID-19 in the Americas and the erosion of human rights for the poor. PLoS Negl Trop Dis. 2020 12; 14(12):e0008954.
    View in: PubMed
    Score: 0.715
  6. Developing a low-cost and accessible COVID-19 vaccine for global health. PLoS Negl Trop Dis. 2020 07; 14(7):e0008548.
    View in: PubMed
    Score: 0.696
  7. COVID-19 vaccines: neutralizing antibodies and the alum advantage. Nat Rev Immunol. 2020 07; 20(7):399-400.
    View in: PubMed
    Score: 0.692
  8. COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020 06; 20(6):347-348.
    View in: PubMed
    Score: 0.684
  9. Central Latin America: Two decades of challenges in neglected tropical disease control. PLoS Negl Trop Dis. 2020 03; 14(3):e0007962.
    View in: PubMed
    Score: 0.680
  10. "Running the Gauntlet": Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a "Call to Action". Hum Vaccin Immunother. 2019; 15(10):2235-2242.
    View in: PubMed
    Score: 0.647
  11. Human anthelminthic vaccines: Rationale and challenges. Vaccine. 2016 06 24; 34(30):3549-55.
    View in: PubMed
    Score: 0.519
  12. Advancing a vaccine to prevent hookworm disease and anemia. Vaccine. 2016 06 03; 34(26):3001-3005.
    View in: PubMed
    Score: 0.515
  13. Neglected tropical diseases in Central America and Panama: review of their prevalence, populations at risk and impact on regional development. Int J Parasitol. 2014 Aug; 44(9):597-603.
    View in: PubMed
    Score: 0.453
  14. Innovation for the 'bottom 100 million': eliminating neglected tropical diseases in the Americas. Adv Exp Med Biol. 2013; 764:1-12.
    View in: PubMed
    Score: 0.412
  15. Chagas disease: "the new HIV/AIDS of the Americas". PLoS Negl Trop Dis. 2012; 6(5):e1498.
    View in: PubMed
    Score: 0.395
  16. An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. Expert Rev Vaccines. 2006 Apr; 5(2):189-98.
    View in: PubMed
    Score: 0.258
  17. A Honduran Prevalence Study on Soil-Transmitted Helminths Highlights Serological Antibodies to Tm-WAP49 as a Diagnostic Marker for Exposure to Human Trichuriasis. Am J Trop Med Hyg. 2025 May 07; 112(5):1017-1025.
    View in: PubMed
    Score: 0.238
  18. The zebrafish as a potential model for vaccine and adjuvant development. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):535-545.
    View in: PubMed
    Score: 0.226
  19. Global regulatory reforms to promote equitable vaccine access in the next pandemic. PLOS Glob Public Health. 2023; 3(10):e0002482.
    View in: PubMed
    Score: 0.217
  20. Vaccine value profile for Hookworm. Vaccine. 2024 07 25; 42(19 Suppl 1):S25-S41.
    View in: PubMed
    Score: 0.217
  21. Neglected tropical disease vaccines: hookworm, leishmaniasis, and schistosomiasis. Vaccine. 2023 11 03; 41 Suppl 2:S176-S179.
    View in: PubMed
    Score: 0.217
  22. Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease. Front Cell Infect Microbiol. 2023; 13:1106315.
    View in: PubMed
    Score: 0.207
  23. Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. Expert Rev Vaccines. 2022 09; 21(9):1185-1203.
    View in: PubMed
    Score: 0.199
  24. Vaxi-DL: A web-based deep learning server to identify potential vaccine candidates. Comput Biol Med. 2022 06; 145:105401.
    View in: PubMed
    Score: 0.195
  25. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. bioRxiv. 2022 Mar 22.
    View in: PubMed
    Score: 0.195
  26. Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. Front Immunol. 2022; 13:800295.
    View in: PubMed
    Score: 0.193
  27. The silent and dangerous inequity around access to COVID-19 testing: A call to action. EClinicalMedicine. 2022 Jan; 43:101230.
    View in: PubMed
    Score: 0.191
  28. Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022 02; 190:106003.
    View in: PubMed
    Score: 0.189
  29. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci Rep. 2021 09 02; 11(1):17626.
    View in: PubMed
    Score: 0.188
  30. Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. EClinicalMedicine. 2021 Sep; 39:101053.
    View in: PubMed
    Score: 0.187
  31. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1. Appl Microbiol Biotechnol. 2021 May; 105(10):4153-4165.
    View in: PubMed
    Score: 0.184
  32. SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 08 03; 17(8):2356-2366.
    View in: PubMed
    Score: 0.183
  33. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim Biophys Acta Gen Subj. 2021 06; 1865(6):129893.
    View in: PubMed
    Score: 0.182
  34. Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members. EClinicalMedicine. 2021 Mar; 33:100780.
    View in: PubMed
    Score: 0.181
  35. SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice. bioRxiv. 2021 Feb 09.
    View in: PubMed
    Score: 0.181
  36. A new patient registry for Chagas disease. PLoS Negl Trop Dis. 2020 10; 14(10):e0008418.
    View in: PubMed
    Score: 0.176
  37. Global COVID-19 Efforts as the Platform to Achieving the Sustainable Development Goals. Curr Trop Med Rep. 2020; 7(4):99-103.
    View in: PubMed
    Score: 0.175
  38. Coronavirus vaccine-associated lung immunopathology-what is the significance? Microbes Infect. 2020 10; 22(9):403-404.
    View in: PubMed
    Score: 0.173
  39. The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. Microbes Infect. 2020 May - Jun; 22(4-5):165-167.
    View in: PubMed
    Score: 0.171
  40. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Hum Vaccin Immunother. 2020 06 02; 16(6):1239-1242.
    View in: PubMed
    Score: 0.171
  41. Will COVID-19 become the next neglected tropical disease? PLoS Negl Trop Dis. 2020 04; 14(4):e0008271.
    View in: PubMed
    Score: 0.170
  42. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020; 7(2):61-64.
    View in: PubMed
    Score: 0.169
  43. Process Characterization and Biophysical Analysis for a Yeast-Expressed Phlebotomus papatasi Salivary Protein (PpSP15) as?a Leishmania Vaccine Candidate. J Pharm Sci. 2020 05; 109(5):1673-1680.
    View in: PubMed
    Score: 0.169
  44. A method to probe protein structure from UV absorbance spectra. Anal Biochem. 2019 12 15; 587:113450.
    View in: PubMed
    Score: 0.164
  45. Advancing the Development of a Human Schistosomiasis Vaccine. Trends Parasitol. 2019 02; 35(2):104-108.
    View in: PubMed
    Score: 0.155
  46. Trichuris muris whey acidic protein induces type 2 protective immunity against whipworm. PLoS Pathog. 2018 08; 14(8):e1007273.
    View in: PubMed
    Score: 0.152
  47. Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease. Infect Immun. 2018 04; 86(4).
    View in: PubMed
    Score: 0.148
  48. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018 03 27; 36(14):1853-1862.
    View in: PubMed
    Score: 0.147
  49. Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. J Pharm Sci. 2018 05; 107(5):1468-1473.
    View in: PubMed
    Score: 0.145
  50. Onchocerca volvulus: The Road from Basic Biology to a Vaccine. Trends Parasitol. 2018 01; 34(1):64-79.
    View in: PubMed
    Score: 0.143
  51. Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. J Pharm Sci. 2017 08; 106(8):1961-1970.
    View in: PubMed
    Score: 0.139
  52. A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. Vaccine. 2017 03 07; 35(10):1410-1416.
    View in: PubMed
    Score: 0.137
  53. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum Vaccin Immunother. 2017 03 04; 13(3):621-633.
    View in: PubMed
    Score: 0.134
  54. Advancing a vaccine to prevent human schistosomiasis. Vaccine. 2016 06 03; 34(26):2988-2991.
    View in: PubMed
    Score: 0.129
  55. Status of vaccine research and development of vaccines for Chagas disease. Vaccine. 2016 06 03; 34(26):2996-3000.
    View in: PubMed
    Score: 0.129
  56. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016 06 03; 34(26):2992-2995.
    View in: PubMed
    Score: 0.128
  57. The BENEFIT Trial: Where Do We Go from Here? PLoS Negl Trop Dis. 2016 Feb; 10(2):e0004343.
    View in: PubMed
    Score: 0.128
  58. New Vaccines for the World's Poorest People. Annu Rev Med. 2016; 67:405-17.
    View in: PubMed
    Score: 0.124
  59. Neglected tropical diseases among the Association of Southeast Asian Nations (ASEAN): overview and update. PLoS Negl Trop Dis. 2015 Apr; 9(4):e0003575.
    View in: PubMed
    Score: 0.121
  60. The Gulf of Mexico: a "hot zone" for neglected tropical diseases? PLoS Negl Trop Dis. 2015 Feb; 9(2):e0003481.
    View in: PubMed
    Score: 0.119
  61. The Onchocerciasis Vaccine for Africa--TOVA--Initiative. PLoS Negl Trop Dis. 2015 Jan; 9(1):e0003422.
    View in: PubMed
    Score: 0.119
  62. Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine. Hum Vaccin Immunother. 2015; 11(6):1474-88.
    View in: PubMed
    Score: 0.118
  63. Toxocariasis in North America: a systematic review. PLoS Negl Trop Dis. 2014 Aug; 8(8):e3116.
    View in: PubMed
    Score: 0.115
  64. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect. 2014 Jul; 16(7):529-31.
    View in: PubMed
    Score: 0.114
  65. Advancing a multivalent 'Pan-anthelmintic' vaccine against soil-transmitted nematode infections. Expert Rev Vaccines. 2014 Mar; 13(3):321-31.
    View in: PubMed
    Score: 0.110
  66. An unfolding tragedy of Chagas disease in North America. PLoS Negl Trop Dis. 2013; 7(10):e2300.
    View in: PubMed
    Score: 0.109
  67. Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis. Hum Vaccin Immunother. 2013 Nov; 9(11):2342-50.
    View in: PubMed
    Score: 0.107
  68. Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis. Hum Vaccin Immunother. 2013 Nov; 9(11):2351-61.
    View in: PubMed
    Score: 0.107
  69. Ears of the Armadillo: Global Health Research and Neglected Diseases in Texas. PLoS Negl Trop Dis. 2013 Jun; 7(6):e2021.
    View in: PubMed
    Score: 0.106
  70. The Human Hookworm Vaccine. Vaccine. 2013 Apr 18; 31 Suppl 2:B227-32.
    View in: PubMed
    Score: 0.105
  71. New vaccines for neglected parasitic diseases and dengue. Transl Res. 2013 Sep; 162(3):144-55.
    View in: PubMed
    Score: 0.105
  72. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis. 2013 Apr; 13(4):342-8.
    View in: PubMed
    Score: 0.104
  73. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012 Dec; 11(12):1405-13.
    View in: PubMed
    Score: 0.102
  74. Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines. 2012 Sep; 11(9):1043-55.
    View in: PubMed
    Score: 0.101
  75. Modeling the economic value of a Chagas' disease therapeutic vaccine. Hum Vaccin Immunother. 2012 Sep; 8(9):1293-301.
    View in: PubMed
    Score: 0.100
  76. Fusion of Na-ASP-2 with human immunoglobulin Fc? abrogates histamine release from basophils sensitized with anti-Na-ASP-2 IgE. Parasite Immunol. 2012 Aug-Sep; 34(8-9):404-11.
    View in: PubMed
    Score: 0.100
  77. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022 06 09; 40(26):3655-3663.
    View in: PubMed
    Score: 0.098
  78. Advances in vaccines against neglected tropical diseases: enhancing physical stability of a recombinant hookworm vaccine through biophysical and formulation studies. Hum Vaccin Immunother. 2012 Jun; 8(6):765-76.
    View in: PubMed
    Score: 0.098
  79. Expression, purification, and molecular analysis of the Necator americanus glutathione S-transferase 1 (Na-GST-1): a production process developed for a lead candidate recombinant hookworm vaccine antigen. Protein Expr Purif. 2012 Jun; 83(2):145-51.
    View in: PubMed
    Score: 0.098
  80. Texas and Mexico: sharing a legacy of poverty and neglected tropical diseases. PLoS Negl Trop Dis. 2012; 6(3):e1497.
    View in: PubMed
    Score: 0.098
  81. Ac-AP-12, a novel factor Xa anticoagulant peptide from the esophageal glands of adult Ancylostoma caninum. Mol Biochem Parasitol. 2011 May; 177(1):42-8.
    View in: PubMed
    Score: 0.090
  82. Molecular cloning, biochemical characterization, and partial protective immunity of the heme-binding glutathione S-transferases from the human hookworm Necator americanus. Infect Immun. 2010 Apr; 78(4):1552-63.
    View in: PubMed
    Score: 0.084
  83. The unfinished public health agenda of chagas disease in the era of globalization. PLoS Negl Trop Dis. 2009 Jul 07; 3(7):e470.
    View in: PubMed
    Score: 0.081
  84. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis. 2008 Sep 24; 2(9):e300.
    View in: PubMed
    Score: 0.077
  85. New technologies for the control of human hookworm infection. Trends Parasitol. 2006 Jul; 22(7):327-31.
    View in: PubMed
    Score: 0.065
  86. Vaccination with recombinant aspartic hemoglobinase reduces parasite load and blood loss after hookworm infection in dogs. PLoS Med. 2005 Oct; 2(10):e295.
    View in: PubMed
    Score: 0.062
  87. Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant protein for use in human clinical trials. Vaccine. 2005 Sep 15; 23(39):4754-64.
    View in: PubMed
    Score: 0.062
  88. mRNA vaccines encoding variant forms of Sm-TSP-2 confer protective immunity against Schistosoma mansoni. Res Sq. 2025 Aug 26.
    View in: PubMed
    Score: 0.062
  89. Antibodies against a secreted protein from hookworm larvae reduce the intensity of hookworm infection in humans and vaccinated laboratory animals. FASEB J. 2005 Oct; 19(12):1743-5.
    View in: PubMed
    Score: 0.061
  90. The Current and Future Burden of Long COVID in the United States. J Infect Dis. 2025 Jul 11; 231(6):1581-1590.
    View in: PubMed
    Score: 0.061
  91. Characteristic profiling of CHO-cell expressed MERS-CoV RBD-Fc. Int J Biol Macromol. 2025 Jun; 311(Pt 2):143678.
    View in: PubMed
    Score: 0.060
  92. Different responses involving Tfh cells delay parasite-specific antibody production in Trypanosoma cruzi acute experimental models. Front Immunol. 2025; 16:1487317.
    View in: PubMed
    Score: 0.060
  93. Hookworm: "the great infection of mankind". PLoS Med. 2005 Mar; 2(3):e67.
    View in: PubMed
    Score: 0.060
  94. Altering the intracellular trafficking of Necator americanus GST-1 antigen yields novel hookworm mRNA vaccine candidates. PLoS Negl Trop Dis. 2025 Jan; 19(1):e0012809.
    View in: PubMed
    Score: 0.059
  95. Helminth infections of children: prospects for control. Adv Exp Med Biol. 2005; 568:135-44.
    View in: PubMed
    Score: 0.059
  96. Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-na?ve adults. PLoS Negl Trop Dis. 2024 Dec 30; 18(12):e0012788.
    View in: PubMed
    Score: 0.059
  97. Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis. EClinicalMedicine. 2025 Jan; 79:102972.
    View in: PubMed
    Score: 0.059
  98. Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate. PLoS Pathog. 2024 Dec; 20(12):e1012764.
    View in: PubMed
    Score: 0.059
  99. Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
    View in: PubMed
    Score: 0.059
  100. Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins. Viruses. 2024 09 20; 16(9).
    View in: PubMed
    Score: 0.058
  101. Hookworm infection. N Engl J Med. 2004 Aug 19; 351(8):799-807.
    View in: PubMed
    Score: 0.058
  102. What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective? J Infect Dis. 2024 Aug 16; 230(2):382-393.
    View in: PubMed
    Score: 0.058
  103. Vaccine value profile for schistosomiasis. Vaccine. 2025 Oct 03; 64:126020.
    View in: PubMed
    Score: 0.057
  104. Parasitic Contamination of Soil in the Southern United States. Am J Trop Med Hyg. 2024 Sep 04; 111(3):506-514.
    View in: PubMed
    Score: 0.057
  105. A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses. NPJ Vaccines. 2024 Jul 22; 9(1):132.
    View in: PubMed
    Score: 0.057
  106. Vaccination of dogs with a recombinant cysteine protease from the intestine of canine hookworms diminishes the fecundity and growth of worms. J Infect Dis. 2004 May 15; 189(10):1952-61.
    View in: PubMed
    Score: 0.056
  107. Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease. ACS Appl Mater Interfaces. 2024 Apr 03; 16(13):15832-15846.
    View in: PubMed
    Score: 0.056
  108. Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial. Lancet Infect Dis. 2024 Jul; 24(7):760-774.
    View in: PubMed
    Score: 0.056
  109. Chagasin from Trypanosoma cruzi as a molecular scaffold to express epitopes of TSA-1 as soluble recombinant chimeras. Protein Expr Purif. 2024 Jun; 218:106458.
    View in: PubMed
    Score: 0.056
  110. Environmental Detection of Parasites in the Marginalized Paiute Reservations Compared to a Nearby Area. Am J Trop Med Hyg. 2024 Mar 06; 110(3):457-459.
    View in: PubMed
    Score: 0.056
  111. Choice of adjuvant and antigen composition alters the immunogenic profile of a SARS-CoV-2 subunit vaccine. Front Drug Deliv. 2024; 4:1342518.
    View in: PubMed
    Score: 0.056
  112. The potential epidemiologic, clinical, and economic value of a universal coronavirus vaccine: a modelling study. EClinicalMedicine. 2024 Feb; 68:102369.
    View in: PubMed
    Score: 0.055
  113. Optimization and revision of the production process of the Necator americanus glutathione S-transferase 1 (Na-GST-1), the lead hookworm vaccine recombinant protein candidate. Hum Vaccin Immunother. 2014; 10(7):1914-25.
    View in: PubMed
    Score: 0.055
  114. The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2023 Nov; 17(11):e0011519.
    View in: PubMed
    Score: 0.055
  115. Environmental detection of parasites in the marginalized Paiute reservations compared to a nearby area. medRxiv. 2023 Oct 25.
    View in: PubMed
    Score: 0.054
  116. Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease. Nat Commun. 2023 10 25; 14(1):6769.
    View in: PubMed
    Score: 0.054
  117. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2. Vaccines (Basel). 2023 Oct 01; 11(10).
    View in: PubMed
    Score: 0.054
  118. Progress in the development of a recombinant vaccine for human hookworm disease: the Human Hookworm Vaccine Initiative. Int J Parasitol. 2003 Sep 30; 33(11):1245-58.
    View in: PubMed
    Score: 0.054
  119. Time to establish an international vaccine candidate pool for potential highly infectious respiratory disease: a community's view. EClinicalMedicine. 2023 Oct; 64:102222.
    View in: PubMed
    Score: 0.054
  120. Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8+ T-cells. Curr Res Immunol. 2023; 4:100066.
    View in: PubMed
    Score: 0.053
  121. Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis. Vaccine. 2023 08 23; 41(37):5400-5411.
    View in: PubMed
    Score: 0.053
  122. The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. bioRxiv. 2023 Jul 12.
    View in: PubMed
    Score: 0.053
  123. Microbiome Alterations Driven by Trypanosoma cruzi Infection in Two Disjunctive Murine Models. Microbiol Spectr. 2023 06 15; 11(3):e0019923.
    View in: PubMed
    Score: 0.053
  124. Vaccines and therapeutics for immunocompromised patients with COVID-19. EClinicalMedicine. 2023 May; 59:101965.
    View in: PubMed
    Score: 0.052
  125. A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area. PLoS Negl Trop Dis. 2023 03; 17(3):e0011236.
    View in: PubMed
    Score: 0.052
  126. A Data-Driven Approach to Construct a Molecular Map of Trypanosoma cruzi to Identify Drugs and Vaccine Targets. Vaccines (Basel). 2023 Jan 26; 11(2).
    View in: PubMed
    Score: 0.052
  127. Localized cardiac metabolic trajectories and post-infectious metabolic sequelae in experimental Chagas disease. Res Sq. 2023 Jan 20.
    View in: PubMed
    Score: 0.052
  128. Vaxi-DL: An Artificial Intelligence-Enabled Platform for Vaccine Development. Methods Mol Biol. 2023; 2673:305-316.
    View in: PubMed
    Score: 0.051
  129. Investigation of urinary metabolomics in a phase I hookworm vaccine trial in Gabon. PLoS One. 2022; 17(9):e0275013.
    View in: PubMed
    Score: 0.051
  130. The Lancet Commission on lessons for the future from the COVID-19 pandemic. Lancet. 2022 10 08; 400(10359):1224-1280.
    View in: PubMed
    Score: 0.050
  131. Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi. Front Cell Infect Microbiol. 2022; 12:869039.
    View in: PubMed
    Score: 0.049
  132. Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study. Lancet Public Health. 2022 04; 7(4):e356-e365.
    View in: PubMed
    Score: 0.049
  133. Reviewing a Decade of Outpatient Tropical Medicine in Houston, Texas. Am J Trop Med Hyg. 2022 Apr 06; 106(4):1049-1056.
    View in: PubMed
    Score: 0.049
  134. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Sci Transl Med. 2022 Jan 26; 14(629):eabj5305.
    View in: PubMed
    Score: 0.048
  135. ASCVac-1, a Multi-Peptide Chimeric Vaccine, Protects Mice Against Ascaris suum Infection. Front Immunol. 2021; 12:788185.
    View in: PubMed
    Score: 0.048
  136. Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon. PLoS Negl Trop Dis. 2021 10; 15(10):e0009732.
    View in: PubMed
    Score: 0.047
  137. Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination. J Infect Dis. 2021 09 17; 224(6):938-948.
    View in: PubMed
    Score: 0.047
  138. Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. PLoS Med. 2021 09; 18(9):e1003772.
    View in: PubMed
    Score: 0.047
  139. Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi. PLoS Negl Trop Dis. 2021 09; 15(9):e0009689.
    View in: PubMed
    Score: 0.047
  140. Signal Transducer and Activator of Transcription-3 Modulation of Cardiac Pathology in Chronic Chagasic Cardiomyopathy. Front Cell Infect Microbiol. 2021; 11:708325.
    View in: PubMed
    Score: 0.047
  141. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 07 15; 6(61).
    View in: PubMed
    Score: 0.046
  142. Potency testing for a recombinant protein vaccine early in clinical development: Lessons from the Schistosoma mansoni Tetraspanin 2 vaccine. Vaccine X. 2021 Aug; 8:100100.
    View in: PubMed
    Score: 0.046
  143. Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment. EClinicalMedicine. 2021 Jun; 36:100925.
    View in: PubMed
    Score: 0.046
  144. Urgent needs to accelerate the race for COVID-19 therapeutics. EClinicalMedicine. 2021 Jun; 36:100911.
    View in: PubMed
    Score: 0.046
  145. Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity. bioRxiv. 2021 May 21.
    View in: PubMed
    Score: 0.046
  146. Alterations to the Cardiac Metabolome Induced by Chronic T. cruzi Infection Relate to the Degree of Cardiac Pathology. ACS Infect Dis. 2021 06 11; 7(6):1638-1649.
    View in: PubMed
    Score: 0.046
  147. Advances in vaccine development for human trichuriasis. Parasitology. 2021 Mar 24; 1-12.
    View in: PubMed
    Score: 0.045
  148. Repeat-Driven Generation of Antigenic Diversity in a Major Human Pathogen,?Trypanosoma cruzi. Front Cell Infect Microbiol. 2021; 11:614665.
    View in: PubMed
    Score: 0.045
  149. Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection. Sci Rep. 2021 02 05; 11(1):3222.
    View in: PubMed
    Score: 0.045
  150. The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine. Am J Prev Med. 2021 05; 60(5):605-613.
    View in: PubMed
    Score: 0.045
  151. Vaccination with chimeric protein induces protection in murine model against ascariasis. Vaccine. 2021 01 08; 39(2):394-401.
    View in: PubMed
    Score: 0.044
  152. Host Immunity and Inflammation to Pulmonary Helminth Infections. Front Immunol. 2020; 11:594520.
    View in: PubMed
    Score: 0.044
  153. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541.
    View in: PubMed
    Score: 0.044
  154. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. Lancet Infect Dis. 2021 02; 21(2):275-285.
    View in: PubMed
    Score: 0.044
  155. A scalable and reproducible manufacturing process for Phlebotomus papatasi salivary protein PpSP15, a vaccine candidate for leishmaniasis. Protein Expr Purif. 2021 01; 177:105750.
    View in: PubMed
    Score: 0.044
  156. Correction: Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults. PLoS Negl Trop Dis. 2020 08; 14(8):e0008670.
    View in: PubMed
    Score: 0.044
  157. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. Am J Prev Med. 2020 10; 59(4):493-503.
    View in: PubMed
    Score: 0.043
  158. TLR4 agonist protects against Trypanosoma cruzi acute lethal infection by decreasing cardiac parasite burdens. Parasite Immunol. 2020 10; 42(10):e12769.
    View in: PubMed
    Score: 0.043
  159. Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement. bioRxiv. 2020 Jul 05.
    View in: PubMed
    Score: 0.043
  160. How Efficacious Must a COVID-19 Coronavirus Vaccine be to Prevent or Stop an Epidemic by Itself. medRxiv. 2020 May 30.
    View in: PubMed
    Score: 0.043
  161. Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques. Vaccine. 2020 06 15; 38(29):4584-4591.
    View in: PubMed
    Score: 0.043
  162. Reproductive Outcomes in Rhesus Macaques (Macaca mulatta) with Naturally-acquired Trypanosoma cruzi Infection. Comp Med. 2020 04 01; 70(2):152-159.
    View in: PubMed
    Score: 0.042
  163. The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. Vaccine. 2020 04 03; 38(16):3261-3270.
    View in: PubMed
    Score: 0.042
  164. Protective immunity elicited by the nematode-conserved As37 recombinant protein against Ascaris suum infection. PLoS Negl Trop Dis. 2020 02; 14(2):e0008057.
    View in: PubMed
    Score: 0.042
  165. The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age. Am J Prev Med. 2020 03; 58(3):370-377.
    View in: PubMed
    Score: 0.042
  166. Improved Biomarker and Imaging Analysis for Characterizing Progressive Cardiac Fibrosis in a Mouse Model of Chronic Chagasic Cardiomyopathy. J Am Heart Assoc. 2019 11 19; 8(22):e013365.
    View in: PubMed
    Score: 0.041
  167. Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans. PLoS Negl Trop Dis. 2019 09; 13(9):e0007730.
    View in: PubMed
    Score: 0.041
  168. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
    View in: PubMed
    Score: 0.041
  169. Response to `letter to the editor: 'Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America'?. Expert Rev Anti Infect Ther. 2019 09; 17(9):673-675.
    View in: PubMed
    Score: 0.041
  170. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2019 05; 13(5):e0007413.
    View in: PubMed
    Score: 0.040
  171. Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019 06 19; 37(28):3704-3714.
    View in: PubMed
    Score: 0.040
  172. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. Expert Rev Anti Infect Ther. 2019 03; 17(3):145-157.
    View in: PubMed
    Score: 0.039
  173. China's shifting neglected parasitic infections in an era of economic reform, urbanization, disease control, and the Belt and Road Initiative. PLoS Negl Trop Dis. 2019 01; 13(1):e0006946.
    View in: PubMed
    Score: 0.039
  174. Ascaris Larval Infection and Lung Invasion Directly Induce Severe Allergic Airway Disease in Mice. Infect Immun. 2018 12; 86(12).
    View in: PubMed
    Score: 0.039
  175. IgG Induced by Vaccination With Ascaris suum Extracts Is Protective Against Infection. Front Immunol. 2018; 9:2535.
    View in: PubMed
    Score: 0.039
  176. Ligand binding properties of two Brugia malayi fatty acid and retinol (FAR) binding proteins and their vaccine efficacies against challenge infection in gerbils. PLoS Negl Trop Dis. 2018 10; 12(10):e0006772.
    View in: PubMed
    Score: 0.038
  177. Covalent vaccination with Trypanosoma cruzi Tc24 induces catalytic antibody production. Parasite Immunol. 2018 Nov; 40(11):e12585.
    View in: PubMed
    Score: 0.038
  178. Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice. Hum Vaccin Immunother. 2019; 15(1):210-219.
    View in: PubMed
    Score: 0.038
  179. Lessons along the Critical Path: Developing Vaccines against Human Helminths. Trends Parasitol. 2018 09; 34(9):747-758.
    View in: PubMed
    Score: 0.038
  180. A novel blood-feeding detoxification pathway in Nippostrongylus brasiliensis L3 reveals a potential checkpoint for arresting hookworm development. PLoS Pathog. 2018 03; 14(3):e1006931.
    View in: PubMed
    Score: 0.037
  181. Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico. PLoS Negl Trop Dis. 2018 01; 12(1):e0006240.
    View in: PubMed
    Score: 0.037
  182. Human Intestinal Parasite Burden and Poor Sanitation in Rural Alabama. Am J Trop Med Hyg. 2017 Nov; 97(5):1623-1628.
    View in: PubMed
    Score: 0.036
  183. Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy. Infect Immun. 2017 09; 85(9).
    View in: PubMed
    Score: 0.035
  184. Identification, Characterization, and Structure of Tm16 from Trichuris muris. J Parasitol Res. 2017; 2017:4342789.
    View in: PubMed
    Score: 0.035
  185. Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response. PLoS Negl Trop Dis. 2017 Jul; 11(7):e0005769.
    View in: PubMed
    Score: 0.035
  186. Mutations to Cysteine Residues in the Trypanosoma cruzi B-Cell Superantigen Tc24 Diminish Susceptibility to IgM-Mediated Hydrolysis. J Parasitol. 2017 10; 103(5):579-583.
    View in: PubMed
    Score: 0.035
  187. Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults. PLoS Negl Trop Dis. 2017 05; 11(5):e0005574.
    View in: PubMed
    Score: 0.035
  188. Structure of SALO, a leishmaniasis vaccine candidate from the sand fly Lutzomyia longipalpis. PLoS Negl Trop Dis. 2017 03; 11(3):e0005374.
    View in: PubMed
    Score: 0.034
  189. Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine. PLoS Negl Trop Dis. 2017 02; 11(2):e0005385.
    View in: PubMed
    Score: 0.034
  190. Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from Leishmania donovani, a vaccine candidate for preventing cutaneous leishmaniasis. Protein Expr Purif. 2017 02; 130:129-136.
    View in: PubMed
    Score: 0.033
  191. The hookworm Ancylostoma ceylanicum intestinal transcriptome provides a platform for selecting drug and vaccine candidates. Parasit Vectors. 2016 Sep 27; 9(1):518.
    View in: PubMed
    Score: 0.033
  192. The Global Economic and Health Burden of Human Hookworm Infection. PLoS Negl Trop Dis. 2016 09; 10(9):e0004922.
    View in: PubMed
    Score: 0.033
  193. The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice. PLoS Negl Trop Dis. 2016 07; 10(7):e0004797.
    View in: PubMed
    Score: 0.033
  194. Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against Brugia malayi Infection. PLoS Negl Trop Dis. 2016 Apr; 10(4):e0004586.
    View in: PubMed
    Score: 0.032
  195. Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. Vaccine. 2016 Apr 27; 34(19):2197-206.
    View in: PubMed
    Score: 0.032
  196. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Hum Vaccin Immunother. 2016 04 02; 12(4):976-87.
    View in: PubMed
    Score: 0.032
  197. Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties. Hum Vaccin Immunother. 2016 07 02; 12(7):1707-20.
    View in: PubMed
    Score: 0.032
  198. Identification and Characterization of the Trypanosoma cruzi B-cell Superantigen Tc24. Am J Trop Med Hyg. 2016 Jan; 94(1):114-121.
    View in: PubMed
    Score: 0.031
  199. Identification of immunodominant antigens for the laboratory diagnosis of toxocariasis. Trop Med Int Health. 2015 Dec; 20(12):1787-96.
    View in: PubMed
    Score: 0.031
  200. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice. Vaccine. 2015 Aug 26; 33(36):4505-12.
    View in: PubMed
    Score: 0.031
  201. New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74. Hum Vaccin Immunother. 2015; 11(5):1251-7.
    View in: PubMed
    Score: 0.030
  202. Limited antigenic variation in the Trypanosoma cruzi candidate vaccine antigen TSA-1. Parasite Immunol. 2014 Dec; 36(12):708-12.
    View in: PubMed
    Score: 0.029
  203. Development of chagas cardiac manifestations among Texas blood donors. Am J Cardiol. 2015 Jan 01; 115(1):113-7.
    View in: PubMed
    Score: 0.029
  204. Trypanosoma cruzi screening in Texas blood donors, 2008-2012. Epidemiol Infect. 2016 Apr; 144(5):1010-3.
    View in: PubMed
    Score: 0.029
  205. Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model. Int J Parasitol. 2014 Aug; 44(9):637-46.
    View in: PubMed
    Score: 0.028
  206. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014; 10(3):648-58.
    View in: PubMed
    Score: 0.028
  207. The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. Vaccine. 2013 Jan 07; 31(3):480-6.
    View in: PubMed
    Score: 0.026
  208. Expression, immunogenicity, histopathology, and potency of a mosquito-based malaria transmission-blocking recombinant vaccine. Infect Immun. 2012 Apr; 80(4):1606-14.
    View in: PubMed
    Score: 0.024
  209. Potency testing for the experimental Na-GST-1 hookworm vaccine. Expert Rev Vaccines. 2010 Oct; 9(10):1219-30.
    View in: PubMed
    Score: 0.022
  210. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. FASEB J. 2009 Sep; 23(9):3007-19.
    View in: PubMed
    Score: 0.020
  211. Reduction of worm fecundity and canine host blood loss mediates protection against hookworm infection elicited by vaccination with recombinant Ac-16. Clin Vaccine Immunol. 2007 Mar; 14(3):281-7.
    View in: PubMed
    Score: 0.017
  212. Ancylostoma caninum MTP-1, an astacin-like metalloprotease secreted by infective hookworm larvae, is involved in tissue migration. Infect Immun. 2006 Feb; 74(2):961-7.
    View in: PubMed
    Score: 0.016
  213. The impact of concurrent and treated Ancylostoma ceylanicum hookworm infections on the immunogenicity of a recombinant hookworm vaccine in hamsters. J Infect Dis. 2006 Jan 01; 193(1):155-62.
    View in: PubMed
    Score: 0.016
  214. Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs. Vaccine. 2006 Jan 23; 24(4):501-9.
    View in: PubMed
    Score: 0.015
  215. Immunogenicity of the hookworm Na-ASP-2 vaccine candidate: characterization of humoral and cellular responses after vaccination in the Sprague Dawley rat. Hum Vaccin. 2005 May-Jun; 1(3):123-8.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.